Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine and Busulfan Conditioning for CML and MDS Transplants
NCT00027924Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2001
- Primary completion
- May 2003
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and busulfan in Chronic Myeloid Leukemia (CML) and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of Nonrelapse Mortality at 100 days. Started Oct 2001; status: completed.
02
Drugs
fludarabinebusulfan
03
Conditions
Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00027924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027924.